Welcure Drugs & Pharmaceuticals Ltd to set up state of the art Agro Pharma Research Laboratory; To Invest Rs. 70-80 crore in the project

Company proposes to raise up to Rs. 80 crore by way of Qualified Institutional Placement (QIP), in one or more tranches

Highlights:

India, August 20, 2025: Welcure Drugs & Pharmaceuticals Ltd (BSE: 524661) is planning to invest around Rs. 70-80 crore in setting up a state-of-the-art cGMP standard research laboratory dedicated for agro pharma research.

Size of the project is estimated to be around Rs. 70-80 crore including laboratory infrastructure, pilot lines, analytics & quality systems). The facilities and processes will be designed to align with applicable cGMP standards and the US FDA’s Botanical Drug Development guidance (as relevant), in order to enable participation in broader international markets for botanical/ayurvedic products, subject to all necessary approvals. The proposed site, timeline and commissioning plan will be finalised post approvals.

Company proposes to raise up to Rs. 80 crore by way of Qualified Institutional Placement (QIP), in one or more tranches to fund the agro pharma research laboratory and for general corporate purposes. Meeting of the Board of Directors will be held on 28 August 2025, to consider and, if deemed appropriate, approve the aforesaid fund-raising by QIP, including approving enabling resolutions, issue structure and seeking shareholders’ approval as may be required.

Objective of the laboratory will be to research, validate and scale processes for conversion of agricultural/botanical inputs into pharma-grade products aimed at public health and societal wellbeing. The above proposals are subject to requisite Board, shareholder, regulatory and statutory approvals and market conditions.

Additionally, Company Board of Director is planning to meet on on Friday August 22, 2025 to consider the proposal of Stock Split and Bonus Issue. Following company’s stellar Q1FY26 financial results, this move is aimed at enhancing liquidity and broadening shareholding.

As per the proposal, the company has suggested Sub-division (Stock Split) of the company’s equity shares in the ratio of 1:10 (i.e. one equity share into ten equity shares), subject to approvals as may be required. The company has also proposed issue of Bonus Shares up to 1:1 (i.e., one bonus equity share for every one equity share held), subject to availability of adequate reserves and receipt of requisite approvals.

These proposals are part of Welcure’s commitment to enhancing market liquidity, expanding retail participation, and improving affordability for investors. These proposals are subject to the Board’s decision and subsequent statutory/ shareholder approvals. If approved, the Company will announce record dates and implementation timelines separately, in accordance with SEBI Listing Obligations and Disclosure Requirements (LODR) and applicable laws.

Speaking on this development, the company management commented, “As a part of our evolving business strategies, we have come up with this proposal for Stock Split and Bonus Issue. These proposals reflect our confidence in Welcure’s growth trajectory and our commitment to enhancing shareholder value. Coupled with our strong financial results and asset-light business model, these steps aim to make Welcure’s shares more accessible and liquid in the market.”

Recently, the company announced its Q1FY26 financial results. Driven by its strategic foray into fee-based export-oriented sourcing services, company’s Revenue from Operations rose sharply to Rs. 299.91 crore in Q1FY26, up from Rs. 21.21 crore in Q4FY25. This represents growth of around 1300% QoQ. Net Profit surged to Rs. 23.29 crore from Rs. 2.50 crore in Q4FY25, marking an 830% increase.

Previously, the company completed seven export-sourcing assignments totalling Rs. 299.91 crore, earning fixed commission income with no inventory or logistics exposure, maintaining its debt-free status. In addition, a Rs. 517 crore global sourcing mandate from Thailand-based Fortune Sagar Impex Company Limited is expected to generate approximately Rs. 25.85 crore in service income during FY26.

About Welcure Drugs & Pharmaceuticals Ltd:

Incorporated in 1992, Welcure Drugs & Pharmaceuticals Ltd is an established pharmaceutical company in India, engaged in the manufacture and trade of a wide range of healthcare formulations. With a focus on quality, compliance, and global integration, Welcure continues to expand its presence in both domestic and international markets.

(Disclosures: At the time of writing this article, author, his clients & dependent family members may have positions in the stocks mentioned above. The author, his firm, his clients or any of his dependent family members may make purchases or sale of the securities mentioned in website. Author may have positions in above stocks so have vested interest obviously in their going up or down as the case may be.

Disclaimer: Investing in any equity is risky. Our recommendations are based on reliable & authenticated sources believed to be true & correct, and also is technical analysis based on & conceived from charts. Investors should take their own decisions. We assume no responsibility for any transactions undertaken by them. The author won't be liable or responsible for any legal or financial losses made by anybody. Investors must take advice from their financial advisors before investing in any stocks.)